Pancreatic Cancer Research

ResearcherHiroshima UniversityActive in the last 2 years

Hiroki Yamaue

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-6982-3457; OpenAlex author ID A5034464730, A5073275097. Sources: ClinicalTrials.gov.

Their work

Papers
74 (first author 12, last author 28)
Trials
6 (principal investigator on 5)
Grants
0
Labs led
1
Collaborators
252
Papers, trials and grants by year

2006: 1 trial · 2007: none · 2008: none · 2009: none · 2010: none · 2011: 4 papers · 2012: 2 papers, 1 trial · 2013: 2 papers · 2014: 3 papers, 2 trials · 2015: 8 papers, 1 trial · 2016: 6 papers, 1 trial · 2017: 7 papers · 2018: 6 papers · 2019: 8 papers · 2020: 7 papers · 2021: 4 papers · 2022: 6 papers · 2023: 4 papers · 2024: 2 papers · 2025: 2 papers · 2026: 3 papers

Papers 50 of 74

  1. Safe Proton Beam Re-irradiation With a Bioabsorbable Spacer in Pancreatic Cancer: A Case Report. Co-author DOI 10.1016/j.ijpt.2026.101311↗
  2. Mesenteric Versus Conventional Approach During Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma (MAPLE-PD trial): A Multicenter Randomized Controlled… Last author DOI 10.1097/sla.0000000000006900↗
  3. Aso Visual Abstract: Comparison between Neoadjuvant Chemoradiotherapy and Chemotherapy for Patients with Resectable Pancreatic Cancer. Co-author DOI 10.1245/s10434-025-18555-4↗
  4. Three Molecular Developmental Pathways of Remnant Pancreatic Cancer After Resection: A Nationwide Project Study of Japan Pancreas Society. Co-author DOI 10.1097/sla.0000000000006444↗
  5. Comparison between Neoadjuvant Chemoradiotherapy and Chemotherapy for Patients with Resectable Pancreatic Cancer. Co-author DOI 10.1245/s10434-025-17988-1↗
  6. Outcomes of patients with initially unresectable pancreatic cancer who underwent conversion surgery after FOLFIRINOX or gemcitabine plus nab-paclitaxel chemoth… Co-author DOI 10.1002/jhbp.12066↗
  7. Short-term serial circulating tumor DNA assessment predicts therapeutic efficacy for patients with advanced pancreatic cancer. Co-author DOI 10.1007/s00432-023-05594-1↗
  8. Efficacy and safety of neoadjuvant nab-paclitaxel plus gemcitabine therapy in patients with borderline resectable pancreatic cancer: A multicenter single-arm p… Last author DOI 10.1002/ags3.12712↗
  9. Impact of S-1 adjuvant chemotherapy longer than 6 months on survival in patients with resected pancreatic cancer: a nationwide survey by the Japan Pancreas Soc… Co-author DOI 10.1002/cncr.34580↗
  10. Features of T1 pancreatic cancer and validation of the eighth edition AJCC staging system definition using a Korean-Japanese joint cohort and the SEER database. Co-author DOI 10.1002/jhbp.1316↗
  11. Radiographic duodenal invasion is associated with poor prognosis and early recurrence in patients with pancreatic ductal adenocarcinoma. Last author DOI 10.1016/j.ejso.2023.06.012↗
  12. Outcomes of lung metastasis from pancreatic cancer: A nationwide multicenter analysis. Co-author DOI 10.1002/jhbp.1127↗
  13. Reply to: Correspondence reading "Complete circumferential lymphadenectomy around the superior mesenteric artery with preservation of nerve plexus reduces loco… First author DOI 10.1016/j.ejso.2021.11.008↗
  14. Supervised Exercise Therapy and Adjuvant Chemotherapy for Pancreatic Cancer: A Prospective, Single-Arm, Phase II Open-Label, Nonrandomized, Historically Contro… Last author DOI 10.1097/xcs.0000000000000408↗
  15. Randomized phase III trial of intravenous and intraperitoneal paclitaxel with S-1 versus gemcitabine plus nab-paclitaxel for pancreatic ductal adenocarcinoma w… Co-author DOI 10.1186/s13063-022-06049-7↗
  16. Circulating Tumor DNA as a Potential Prognostic Marker in Patients with Borderline-Resectable Pancreatic Cancer Undergoing Neoadjuvant Chemotherapy Followed by… Last author DOI 10.1245/s10434-021-10985-0↗
  17. Kras Gene Analysis Using Liquid-Based Cytology Specimens Predicts Therapeutic Responses and Prognosis in Patients with Pancreatic Cancer. Co-author DOI 10.3390/cancers14030551↗
  18. Advances in immunotherapy for pancreatic ductal adenocarcinoma. Last author DOI 10.1002/jhbp.944↗
  19. Complete circumferential lymphadenectomy around the superior mesenteric artery with preservation of nerve plexus reduces locoregional recurrence after pancreat… Last author DOI 10.1016/j.ejso.2021.06.005↗
  20. Left-sided Portal Hypertension After Pancreaticoduodenectomy With Resection of the Portal Vein/Superior Mesenteric Vein Confluence in Patients With Pancreatic … Co-author DOI 10.1097/sla.0000000000003487↗
  21. Covered self-expandable metal stents versus plastic stents for preoperative biliary drainage in patient receiving neo-adjuvant chemotherapy for borderline rese… Co-author DOI 10.1111/den.13926↗
  22. Diffusion-weighted MRI predicts the histologic response for neoadjuvant therapy in patients with pancreatic cancer: a prospective study (DIFFERENT trial). Last author DOI 10.1007/s00423-020-01857-4↗
  23. Fully covered self-expandable metal stent with an anti-migration system vs plastic stent for distal biliary obstruction caused by borderline resectable pancrea… First author DOI 10.1097/md.0000000000018718↗
  24. Optimal Treatment for Octogenarians With Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma: A Multicenter Retrospective Study. Co-author DOI 10.1097/mpa.0000000000001579↗
  25. [Surgical treatment for resectable pancreatic cancer]. First author DOI 10.11405/nisshoshi.117.302↗
  26. Preoperative In-Hospital Rehabilitation Improves Physical Function in Patients with Pancreatic Cancer Scheduled for Surgery. Last author DOI 10.1620/tjem.251.279↗
  27. Preoperative Scoring System to Predict Prognosis in Patients Who Undergo Neoadjuvant Therapy for Pancreatic Cancer. Last author DOI 10.21873/anticanres.14399↗
  28. Utility of Contrast-Enhanced Harmonic Endoscopic Ultrasonography for Early Diagnosis of Small Pancreatic Cancer. Co-author DOI 10.3390/diagnostics10010023↗
  29. Sustained Elevation of Postoperative Serum Level of Carbohydrate Antigen 19-9 is High-Risk Stigmata for Primary Hepatic Recurrence in Patients with Curatively … Co-author DOI 10.1007/s00268-018-4814-4↗
  30. Low lymphocyte monocyte ratio after neoadjuvant therapy predicts poor survival after pancreatectomy in patients with borderline resectable pancreatic cancer. Last author DOI 10.1016/j.surg.2018.12.015↗
  31. Prognostic importance of peritoneal washing cytology in patients with otherwise resectable pancreatic ductal adenocarcinoma who underwent pancreatectomy: A nat… Co-author DOI 10.1016/j.surg.2019.06.023↗
  32. Randomized phase II/III trial of neoadjuvant chemotherapy with gemcitabine and S-1 versus upfront surgery for resectable pancreatic cancer (Prep-02/JSAP05). Co-author DOI 10.1093/jjco/hyy190↗
  33. Neoadjuvant FOLFIRINOX in Patients With Borderline Resectable Pancreatic Cancer: A Systematic Review and Patient-Level Meta-Analysis. Co-author DOI 10.1093/jnci/djz073↗
  34. Decreased serum carbohydrate antigen 19-9 levels after neoadjuvant therapy predict a better prognosis for patients with pancreatic adenocarcinoma: a multicente… Co-author DOI 10.1186/s12885-019-5460-4↗
  35. A double-blind randomized comparative clinical trial to evaluate the safety and efficacy of dendritic cell vaccine loaded with WT1 peptides (TLP0-001) in combi… Last author DOI 10.1186/s13063-019-3332-5↗
  36. Clinical Impact of Neoadjuvant Chemotherapy and Chemoradiotherapy in Borderline Resectable Pancreatic Cancer: Analysis of 884 Patients at Facilities Specializi… Co-author DOI 10.1245/s10434-018-07131-8↗
  37. Distal Pancreatectomy with Celiac Axis Resection (DP-CAR) for Pancreatic Cancer. How I do It. Co-author DOI 10.1007/s11605-018-3894-7↗
  38. Is distal pancreatectomy with en-bloc celiac axis resection effective for patients with locally advanced pancreatic ductal adenocarcinoma? -Multicenter surgica… Co-author DOI 10.1016/j.pan.2017.11.005↗
  39. Resection for recurrent pancreatic cancer in the remnant pancreas after pancreatectomy is clinically promising: Results of a project study for pancreatic surge… Co-author DOI 10.1016/j.surg.2018.05.050↗
  40. MAPLE-PD trial (Mesenteric Approach vs. Conventional Approach for Pancreatic Cancer during Pancreaticoduodenectomy): study protocol for a multicenter randomize… Last author DOI 10.1186/s13063-018-3002-z↗
  41. Identification of a novel HLA-A24-restricted cytotoxic T lymphocyte epitope peptide derived from mesothelin in pancreatic cancer. Last author DOI 10.18632/oncotarget.25837↗
  42. [Evidence of Neoadjuvant Treatment for Pancreatic Cancer]. First author PMID 30382034↗
  43. Mesenteric approach during pancreaticoduodenectomy for pancreatic ductal adenocarcinoma. Last author DOI 10.1002/ags3.12013↗
  44. Phase II clinical trial using novel peptide cocktail vaccine as a postoperative adjuvant treatment for surgically resected pancreatic cancer patients. Last author DOI 10.1002/ijc.30510↗
  45. Retrospective Study of the Correlation Between Pathological Tumor Size and Survival After Curative Resection of T3 Pancreatic Adenocarcinoma: Proposal for Recl… Last author DOI 10.1007/s00268-017-4077-5↗
  46. Multicenter, randomized, open-label Phase II study comparing S-1 alternate-day oral therapy with the standard daily regimen as a first-line treatment in patien… Co-author DOI 10.1007/s00280-017-3250-8↗
  47. Current advance and future foresight of surgical treatment for pancreatic cancer. First author DOI 10.11405/nisshoshi.114.607↗
  48. Effect of Neoadjuvant Nab-Paclitaxel plus Gemcitabine Therapy on Overall Survival in Patients with Borderline Resectable Pancreatic Cancer: A Prospective Multi… Last author DOI 10.1159/000478660↗
  49. Phase I Study of Nab-Paclitaxel plus Gemcitabine as Neoadjuvant Therapy for Borderline Resectable Pancreatic Cancer. Last author DOI 10.21873/anticanres.11389↗
  50. Prognosis after surgical treatment for pancreatic cancer in patients aged 80 years or older: a multicenter study. Co-author DOI 10.1002/jhbp.320↗

Trials 6

  1. Combined Resection vs. Separated Resection After Mobilization of Splenic Vein During Distal Pancreatectomy Principal investigator NCT02871804↗
  2. Phase I Study of Neoadjuvant Chemotherapy for Patients With Borderline Resectable Pancreatic Cancer. Principal investigator NCT02506803↗
  3. Neoadjuvant FIRINOX for Borderline Resectable Pancreatic Cancer - a Pilot Study Principal investigator NCT02148549↗
  4. A Prospective, Multi-center Trial for Reinforced Staple During Distal Pancreatectomy Principal investigator NCT02270554↗
  5. Daikenchuto for Intestinal Dysmotility and Prevention of Postoperative Paralytic Ielus After Pancreaticoduodenectomy Principal investigator NCT01607307↗
  6. Gemcitabine With Antiangiogenic Peptide Vaccine Therapy in Patients With Pancreatic Cancer Study chair NCT00622622↗

Closest collaborators

The 25 strongest of 252 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Seiko Hirono · 34 shared papers, 2012–2026 · strength 3.54
  2. Manabu Kawai · 37 shared papers, 2011–2024 · strength 3.30
  3. Sohei Satoi · 31 shared papers, 2013–2026 · strength 2.63
  4. Ken‐ichi Okada · 28 shared papers, 2012–2024 · strength 2.54
  5. Motoki Miyazawa · 24 shared papers, 2011–2024 · strength 2.14
  6. Yuji Kitahata · 19 shared papers, 2012–2026 · strength 2.08
  7. Michiaki Unno · 23 shared papers, 2014–2026 · strength 1.97
  8. Masayuki Sho · 23 shared papers, 2013–2026 · strength 1.89
  9. Yoshiaki Murakami · 19 shared papers, 2014–2026 · strength 1.47
  10. Goro Honda · 16 shared papers, 2014–2026 · strength 1.26
  11. Ippei Matsumoto · 17 shared papers, 2014–2024 · strength 1.12
  12. Masaji Tani · 14 shared papers, 2012–2025 · strength 1.05
  13. Tsutomu Fujii · 11 shared papers, 2016–2025 · strength 1.04
  14. Itaru Endo · 7 shared papers, 2019–2026 · strength 0.98
  15. Satoshi Hirano · 7 shared papers, 2013–2026 · strength 0.95
  16. Kenichiro Uemura · 13 shared papers, 2015–2026 · strength 0.93
  17. Masayuki Ohtsuka · 5 shared papers, 2023–2026 · strength 0.89
  18. Fuyuhiko Motoi · 14 shared papers, 2014–2022 · strength 0.82
  19. Atsushi Shimizu · 10 shared papers, 2012–2024 · strength 0.81
  20. Tomohisa Yamamoto · 8 shared papers, 2015–2025 · strength 0.80
  21. Hidetoshi Eguchi · 9 shared papers, 2013–2025 · strength 0.78
  22. Yuichi Nagakawa · 6 shared papers, 2018–2026 · strength 0.78
  23. Suguru Yamada · 6 shared papers, 2017–2026 · strength 0.73
  24. Hideki Motobayashi · 4 shared papers, 2022–2026 · strength 0.71
  25. Masayuki Kitano · 7 shared papers, 2017–2023 · strength 0.67

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.